The company specializes in developing immunotherapies targeting cancer and autoimmune diseases through its proprietary Myeloid Engager Platform. This platform is designed to activate monocytes and macrophages to enhance anti-tumor immunity while minimizing systemic inflammation.​

In July 2024, LTZ completed a Series A financing round, raising over $20 million. The round was led by Lapam Capital, with participation from GL Ventures, K2 Venture Partners, and Shunwei Capital. This brought the company's total funding to approximately $50 million since its inception. ​

The lead candidate, LTZ-301, is a bispecific antibody targeting CD79b-positive B cells, aiming to treat relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for LTZ-301 in February 2025, with a Phase 1 clinical trial planned to commence in the second quarter of 2025. ​

Another program, LTZ-232, is in the IND-enabling stage, targeting additional oncology and autoimmune indications. The company also has discovery-stage programs focusing on solid tumors and immune-mediated diseases.​